Neuroendocrine Tumors (NETs) - Epidemiology Forecast to 2027

  • ID: 4564675
  • Report
  • 125 pages
  • DelveInsight
1 of 3
‘Neuroendocrine Tumors (NETs) - Epidemiology Forecast to 2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Neuroendocrine Tumors (NETs) in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

Geography Covered:
  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan
Study Period:: 2016-2027

Neuroendocrine Tumors Epidemiology

The Neuroendocrine Tumors epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. The epidemiology data for Neuroendocrine Tumors are studied through all possible division to give a better understanding about the Disease scenario in 7MM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Neuroendocrine Tumors Epidemiology Segmentation

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [total prevalent cases, total incident cases, diagnosed prevalent cases, symptom based classification of NETs (asymptomatic and symptomatic), diagnosed prevalence based on malignancy (Malignant and non-malignant), site specific incident cases (Gastroenteropancreatic, lung and other sites), Grade-wise prevalent cases (Grade I, Grade II and Grade III) and stage-wise prevalent cases (localized, regional and distant) scenario of Neuroendocrine Tumors (NETs) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.

The report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

According to this research, the total prevalent population of Neuroendocrine Tumors (NETs) was found to be 442,100 in the year 2016 in 7MM.

Report Scope:
  • The report covers detailed overview of Neuroendocrine Tumors explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The report provides the insight about the historical and forecasted patient pool of Neuroendocrine Tumors in 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
  • The Report assesses the disease risk and burden and highlights the unmet needs of the disease
  • The Report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report provides the segmentation of the disease epidemiology by symptoms, malignancy, site-specific, stage-wise and grade-wise population of NETs in 7MM
Key strengths:
  • 10 Year Forecast of Neuroendocrine Tumors epidemiology
  • 7MM Coverage
  • Total Prevalent Cases of Neuroendocrine Tumors
  • Prevalent Cases according to segmentation: Symptoms, Malignancy, Site-specific, Stage-wise and Grade-wise
  • Diagnosed cases of NETs
Key assessments:
  • Patient Segmentation
  • Disease Risk & Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population
READ MORE
Note: Product cover images may vary from those shown
2 of 3
1. Key Insights

2. Disease Background and Overview: Neuroendocrine Tumors (NETs)
2.1.1. Introduction
2.1.2. Classification of Neuroendocrine Tumors
2.1.3. Causes
2.1.4. Risk Factors
2.1.5. Symptoms
2.1.6. Pathophysiology
2.1.7. Diagnosis
2.1.7.1. Grading of NETs
2.1.7.2. Staging of NETs

3. Epidemiology and Patient Population
3.1.1. Key Findings
3.1.2. 7MM Total Prevalent Patient Population of NETs
3.1.3. Total Incident Patient Population of NETs
3.1.4. Country Wise-Epidemiology of NETs
3.1.5. United States
3.1.5.1. Total Prevalent Cases of NETs in the United States
3.1.5.2. Total Incident Cases of NETs in the United States
3.1.5.3. Diagnosed prevalent cases of NETs in the United States
3.1.5.4. Symptom based classification of NETs
3.1.5.5. Diagnosed prevalent cases based on Malignancy
3.1.5.6. Site-specific prevalent cases of NETs
3.1.5.7. Grade-wise prevalent cases of NETs
3.1.5.8. Stage-wise prevalent cases of NETs
3.1.6. EU5 Countries
3.1.7. Germany
3.1.7.1. Total Prevalent Cases of NETs in Germany
3.1.7.2. Total Incident Cases of NETs in Germany
3.1.7.3. Diagnosed prevalent cases of NETs in Germany
3.1.7.4. Symptom based classification of NETs
3.1.7.5. Diagnosed prevalent cases based on Malignancy
3.1.7.6. Site-specific prevalent cases of NETs
3.1.7.7. Grade-wise prevalent cases of NETs
3.1.7.8. Stage-wise prevalent cases of NETs
3.1.8. France
3.1.8.1. Total Prevalent Cases of NETs in France
3.1.8.2. Total Incident Cases of NETs in France
3.1.8.3. Diagnosed prevalent cases of NETs in France
3.1.8.4. Symptom based classification of NETs
3.1.8.5. Diagnosed prevalent cases based on Malignancy
3.1.8.6. Site-specific prevalent cases of NETs
3.1.8.7. Grade-wise prevalent cases of NETs
3.1.8.8. Stage-wise prevalent cases of NETs
3.1.9. Italy
3.1.9.1. Total Prevalent Cases of NETs in Italy
3.1.9.2. Total Incident Cases of NETs in Italy
3.1.9.3. Diagnosed prevalent cases of NETs in Italy
3.1.9.4. Symptom based classification of NETs
3.1.9.5. Diagnosed prevalent cases based on Malignancy
3.1.9.6. Site-specific prevalent cases of NETs
3.1.9.7. Grade-wise prevalent cases of NETs
3.1.9.8. Stage-wise prevalent cases of NETs
3.1.10. Spain
3.1.10.1. Total Prevalent Cases of NETs in Spain
3.1.10.2. Total Incident Cases of NETs in Spain
3.1.10.3. Diagnosed prevalent cases of NETs in Spain
3.1.10.4. Symptom based classification of NETs
3.1.10.5. Diagnosed prevalent cases based on Malignancy
3.1.10.6. Site-specific prevalent cases of NETs
3.1.10.7. Grade-wise prevalent cases of NETs
3.1.10.8. Stage-wise prevalent cases of NETs
3.1.11. United Kingdom
3.1.11.1. Total Prevalent Cases of NETs in the UK
3.1.11.2. Total Incident Cases of NETs in the UK
3.1.11.3. Diagnosed prevalent cases of NETs in the UK
3.1.11.4. Symptom based classification of NETs
3.1.11.5. Diagnosed prevalent cases based on Malignancy
3.1.11.6. Site-specific prevalent cases of NETs
3.1.11.7. Grade-wise prevalent cases of NETs
3.1.11.8. Stage-wise prevalent cases of NETs
3.1.12. Japan
3.1.12.1. Total Prevalent Cases of NETs in Japan
3.1.12.2. Total Incident Cases of NETs in Japan
3.1.12.3. Diagnosed prevalent cases of NETs in Japan
3.1.12.4. Symptom based classification of NETs
3.1.12.5. Diagnosed prevalent cases based on Malignancy
3.1.12.6. Site-specific prevalent cases of NETs
3.1.12.7. Grade-wise prevalent cases of NETs
3.1.12.8. Stage-wise prevalent cases of NETs

4. Appendix
4.1. Report Methodology

5. Capabilities

6. Disclaimer

7. About the Publisher

List of Tables
Table 1: Clinical syndrome of functional and non-functional pancreatic neuroendocrine tumors
Table 2: Systems of nomenclature for NETs
Table 3: Grading systems for NETs
Table 4: Total Prevalent Population of NETs in the 7MM (2016-2027)
Table 5: Total Incident Population of NETs in the 7MM (2016-2027)
Table 6: Total Prevalent Cases of NETs in the United States (2016-2027)
Table 7: Total Incident Cases of NETs in the United States (2016-2027)
Table 8: Diagnosed prevalent cases of NETs in the United States (2016-2027)
Table 9: Symptom based classification of NETs in the United States (2016-2027)
Table 10: Diagnosed prevalent cases based on Malignancy in the United States (2016-2027)
Table 11: Site-specific prevalent cases of NETs in the United States (2016-2027)
Table 12: Grade-wise prevalent cases of NETs in the United States (2016-2027)
Table 13: Stage-wise prevalent cases of NETs in the United States (2016-2027)
Table 14: Total Prevalent Cases of NETs in Germany (2016-2027)
Table 15: Total Incident Cases of NETs in Germany (2016-2027)
Table 16: Diagnosed prevalent cases of NETs in Germany (2016-2027)
Table 17: Symptom based classification of NETs in Germany (2016-2027)
Table 18: Diagnosed prevalent cases based on Malignancy in Germany (2016-2027)
Table 19: Site-specific prevalent cases of NETs in Germany (2016-2027)
Table 20: Grade-wise prevalent cases of NETs in Germany (2016-2027)
Table 21: Stage-wise prevalent cases of NETs in Germany (2016-2027)
Table 22: Total Prevalent Cases of NETs in France (2016-2027)
Table 23: Total Incident Cases of NETs in France (2016-2027)
Table 24: Diagnosed prevalent cases of NETs in France (2016-2027)
Table 25: Symptom based classification of NETs in France (2016-2027)
Table 26: Diagnosed prevalent cases based on Malignancy in France (2016-2027)
Table 27: Site-specific prevalent cases of NETs in France (2016-2027)
Table 28: Grade-wise prevalent cases of NETs in France (2016-2027)
Table 29: Stage-wise prevalent cases of NETs in France (2016-2027)
Table 30: Total Prevalent Cases of NETs in Italy (2016-2027)
Table 31: Total Incident Cases of NETs in Italy (2016-2027)
Table 32: Diagnosed prevalent cases of NETs in Italy (2016-2027)
Table 33: Symptom based classification of NETs in Italy (2016-2027)
Table 34: Diagnosed prevalent cases based on Malignancy in Italy (2016-2027)
Table 35: Site-specific prevalent cases of NETs in Italy (2016-2027)
Table 36: Grade-wise prevalent cases of NETs in Italy (2016-2027)
Table 37: Stage-wise prevalent cases of NETs in Italy (2016-2027)
Table 38: Total Prevalent Cases of NETs in Spain (2016-2027)
Table 39: Total Incident Cases of NETs in Spain (2016-2027)
Table 40: Diagnosed prevalent cases of NETs in Spain (2016-2027)
Table 41: Symptom based classification of NETs in Spain (2016-2027)
Table 42: Diagnosed prevalent cases based on Malignancy in Spain (2016-2027)
Table 43: Site-specific prevalent cases of NETs in Spain (2016-2027)
Table 44: Grade-wise prevalent cases of NETs in Spain (2016-2027)
Table 45: Stage-wise prevalent cases of NETs in Spain (2016-2027)
Table 46: Total Prevalent Cases of NETs in the UK (2016-2027)
Table 47: Total Incident Cases of NETs in the UK (2016-2027)
Table 48: Diagnosed prevalent cases of NETs in the UK (2016-2027)
Table 49: Symptom based classification of NETs in the UK (2016-2027)
Table 50: Diagnosed prevalent cases based on Malignancy in the UK (2016-2027)
Table 51: Site-specific prevalent cases of NETs in the UK(2016-2027)
Table 52: Grade-wise prevalent cases of NETs in the UK (2016-2027)
Table 53: Stage-wise prevalent cases of NETs in the UK (2016-2027)
Table 54: Total Prevalent Cases of NETs in Japan (2016-2027)
Table 55: Total Incident Cases of NETs in Japan (2016-2027)
Table 56: Diagnosed prevalent cases of NETs in Japan (2016-2027)
Table 57: Symptom based classification of NETs in Japan (2016-2027)
Table 58: Diagnosed prevalent cases based on Malignancy in Japan (2016-2027)
Table 59: Site-specific prevalent cases of NETs in Japan (2016-2027)
Table 60: Grade-wise prevalent cases of NETs in Japan (2016-2027)
Table 61: Stage-wise prevalent cases of NETs in Japan (2016-2027)

List of Figures
Figure 1: Classification of Neuroendocrine Tumors
Figure 2: Causes of Neuroendocrine Tumors
Figure 3: Targeting critical signaling pathways in NETs
Figure 4: Total Prevalent Population of NETs in the 7MM (2016-2027)
Figure 5: Total Incident Population of NETs in the 7MM (2016-2027)
Figure 6: Total Prevalent cases of NETs in the United States (2016-2027)
Figure 7: Total Incident cases of NETs in the United States (2016-2027)
Figure 8: Diagnosed prevalent cases of NETs in the United States (2016-2027)
Figure 9: Symptom based classification of NETs in the United States (2016-2027)
Figure 10: Diagnosed prevalent cases based on Malignancy in the United States (2016-2027)
Figure 11: Site-specific prevalent cases of NETs in the United States (2016-2027)
Figure 12: Grade-wise prevalent cases of NETs in the United States (2016-2027)
Figure 13: Stage-wise prevalent cases of NETs in the United States (2016-2027)
Figure 14: Total Prevalent cases of NETs in Germany (2016-2027)
Figure 15: Total Incident cases of NETs in Germany (2016-2027)
Figure 16: Diagnosed prevalent cases of NETs in Germany (2016-2027)
Figure 17: Symptom based classification of NETs in Germany (2016-2027)
Figure 18: Diagnosed prevalent cases based on Malignancy in Germany (2016-2027)
Figure 19: Site-specific prevalent cases of NETs in Germany (2016-2027)
Figure 20: Grade-wise prevalent cases of NETs in Germany (2016-2027)
Figure 21: Stage-wise prevalent cases of NETs in Germany (2016-2027)
Figure 22: Total Prevalent cases of NETs in France (2016-2027)
Figure 23: Total Incident cases of NETs in France (2016-2027)
Figure 24: Diagnosed prevalent cases of NETs in France (2016-2027)
Figure 25: Symptom based classification of NETs in France (2016-2027)
Figure 26: Diagnosed prevalent cases based on Malignancy in France (2016-2027)
Figure 27: Site-specific prevalent cases of NETs in France (2016-2027)
Figure 28: Grade-wise prevalent cases of NETs in France (2016-2027)
Figure 29: Stage-wise prevalent cases of NETs in France (2016-2027)
Figure 30: Total Prevalent cases of NETs in Italy (2016-2027)
Figure 31: Total Incident cases of NETs in Italy (2016-2027)
Figure 32: Diagnosed prevalent cases of NETs in Italy (2016-2027)
Figure 33: Symptom based classification of NETs in Italy (2016-2027)
Figure 34: Diagnosed prevalent cases based on Malignancy in Italy (2016-2027)
Figure 35: Site-specific prevalent cases of NETs in Italy (2016-2027)
Figure 36: Grade-wise prevalent cases of NETs in Italy (2016-2027)
Figure 37: Stage-wise prevalent cases of NETs in Italy (2016-2027)
Figure 38: Total Prevalent cases of NETs in the Spain (2016-2027)
Figure 39: Total Incident cases of NETs in Spain (2016-2027)
Figure 40: Diagnosed prevalent cases of NETs in Spain (2016-2027)
Figure 41: Symptom based classification of NETs in Spain (2016-2027)
Figure 42: Diagnosed prevalent cases based on Malignancy in Spain (2016-2027)
Figure 43: Site-specific prevalent cases of NETs in Spain (2016-2027)
Figure 44: Grade-wise prevalent cases of NETs in Spain (2016-2027)
Figure 45: Stage-wise prevalent cases of NETs in Spain (2016-2027)
Figure 46: Total Prevalent cases of NETs in the UK (2016-2027)
Figure 47: Total Incident cases of NETs in the UK (2016-2027)
Figure 48: Diagnosed prevalent cases of NETs in the UK (2016-2027)
Figure 49: Symptom based classification of NETs in the UK (2016-2027)
Figure 50: Diagnosed prevalent cases based on Malignancy in the UK (2016-2027)
Figure 51: Site-specific prevalent cases of NETs in the UK (2016-2027)
Figure 52: Grade-wise prevalent cases of NETs in the UK (2016-2027)
Figure 53: Stage-wise prevalent cases of NETs in the UK (2016-2027)
Figure 54: Total Prevalent cases of NETs in Japan (2016-2027)
Figure 55: Total Incident cases of NETs in Japan (2016-2027)
Figure 56: Diagnosed prevalent cases of NETs in Japan (2016-2027)
Figure 57: Symptom based classification of NETs in Japan (2016-2027)
Figure 58: Diagnosed prevalent cases based on Malignancy in Japan (2016-2027)
Figure 59: Site-specific prevalent cases of NETs in Japan (2016-2027)
Figure 60: Grade-wise prevalent cases of NETs in Japan (2016-2027)
Figure 61: Stage-wise prevalent cases of NETs in Japan (2016-2027)
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll